Multiple 30-Month Stays Remain Possible Under Waxman/Hatch Reforms
Multiple 30-month stays on abbreviated new drug applications are still an option in some cases, an FDA 1draft guidance says
Multiple 30-month stays on abbreviated new drug applications are still an option in some cases, an FDA 1draft guidance says